Tags

Type your tag names separated by a space and hit enter

Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo.
Z Gastroenterol. 2009 Feb; 47(2):209-14.ZG

Abstract

BACKGROUND

Therapy trials with bacterial compounds in irritable bowel syndrome (IBS) have produced conflicting results and, so far, an E.-coli preparation has not been used.

METHODS

Two hundred and ninety-eight patients with lower abdominal symptoms diagnosed as IBS were treated for 8 weeks by the compound Symbioflor-2 (Symbiopharm GmbH, Herborn, Germany), an Escherichia coli product (N = 148), or placebo (n = 150) in a double-blinded, randomized fashion. Patients were seen weekly by the physician, who assessed the presence of core IBS symptoms. Both an abdominal pain score (APS) as well as a general symptom score (GSS) were used as primary endpoints. Responders had to have complete absence of IBS core symptoms at > or = 1 visit during treatment.

RESULTS

The responder rate in GSS to the drug was 27 / 148 (18.2 %) in comparison to placebo with 7 / 150 (4.67 %) (p = 0.000397). The improvement in APS was 28 / 148 (18.9 %) and 10 / 150 (6.67 %) for placebo (p = 0.001649). The response was reached from visit 3 onwards with both medication and placebo. Post-hoc analysis revealed no significant differences in efficacy of the drug between the gender and different age groups.

CONCLUSION

Treatment of IBS with the probiotic Symbioflor-2 is effective and superior to placebo in reducing typical symptoms of IBS patients seen by general practitioners and by gastroenterologists.

Authors+Show Affiliations

Internal Medicine VI, University Medical Hospital, Tübingen, Germany. paul.enck@uni-tuebingen.deNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

19197823

Citation

Enck, P, et al. "Randomized Controlled Treatment Trial of Irritable Bowel Syndrome With a Probiotic E.-coli Preparation (DSM17252) Compared to Placebo." Zeitschrift Fur Gastroenterologie, vol. 47, no. 2, 2009, pp. 209-14.
Enck P, Zimmermann K, Menke G, et al. Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo. Z Gastroenterol. 2009;47(2):209-14.
Enck, P., Zimmermann, K., Menke, G., & Klosterhalfen, S. (2009). Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo. Zeitschrift Fur Gastroenterologie, 47(2), 209-14. https://doi.org/10.1055/s-2008-1027702
Enck P, et al. Randomized Controlled Treatment Trial of Irritable Bowel Syndrome With a Probiotic E.-coli Preparation (DSM17252) Compared to Placebo. Z Gastroenterol. 2009;47(2):209-14. PubMed PMID: 19197823.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo. AU - Enck,P, AU - Zimmermann,K, AU - Menke,G, AU - Klosterhalfen,S, Y1 - 2009/02/05/ PY - 2009/2/7/entrez PY - 2009/2/7/pubmed PY - 2009/4/25/medline SP - 209 EP - 14 JF - Zeitschrift fur Gastroenterologie JO - Z Gastroenterol VL - 47 IS - 2 N2 - BACKGROUND: Therapy trials with bacterial compounds in irritable bowel syndrome (IBS) have produced conflicting results and, so far, an E.-coli preparation has not been used. METHODS: Two hundred and ninety-eight patients with lower abdominal symptoms diagnosed as IBS were treated for 8 weeks by the compound Symbioflor-2 (Symbiopharm GmbH, Herborn, Germany), an Escherichia coli product (N = 148), or placebo (n = 150) in a double-blinded, randomized fashion. Patients were seen weekly by the physician, who assessed the presence of core IBS symptoms. Both an abdominal pain score (APS) as well as a general symptom score (GSS) were used as primary endpoints. Responders had to have complete absence of IBS core symptoms at > or = 1 visit during treatment. RESULTS: The responder rate in GSS to the drug was 27 / 148 (18.2 %) in comparison to placebo with 7 / 150 (4.67 %) (p = 0.000397). The improvement in APS was 28 / 148 (18.9 %) and 10 / 150 (6.67 %) for placebo (p = 0.001649). The response was reached from visit 3 onwards with both medication and placebo. Post-hoc analysis revealed no significant differences in efficacy of the drug between the gender and different age groups. CONCLUSION: Treatment of IBS with the probiotic Symbioflor-2 is effective and superior to placebo in reducing typical symptoms of IBS patients seen by general practitioners and by gastroenterologists. SN - 0044-2771 UR - https://www.unboundmedicine.com/medline/citation/19197823/Randomized_controlled_treatment_trial_of_irritable_bowel_syndrome_with_a_probiotic_E__coli_preparation__DSM17252__compared_to_placebo_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2008-1027702 DB - PRIME DP - Unbound Medicine ER -